EIP
JAZZ icon

Ellis Investment Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ellis Investment Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.67M Hold
6,912
– – 0.25% 82
2026
Q1 		$1.31M Buy
6,912
+459
+7% +$80.2K 0.23% 93
2025
Q4 		$1.1M Buy
6,453
+59
+0.9% +$9.04K 0.19% 99
2025
Q3 		$843K Buy
6,394
+349
+6% +$41.9K 0.15% 113
2025
Q2 		$641K Buy
6,045
+707
+13% +$76.8K 0.12% 130
2025
Q1 		$663K Buy
5,338
+191
+4% +$24.9K 0.14% 122
2024
Q4 		$634K Sell
5,147
-666
-11% -$78.5K 0.12% 125
2024
Q3 		$648K Sell
5,813
-112
-2% -$12.3K 0.13% 130
2024
Q2 		$632K Sell
5,925
-3,280
-36% -$361K 0.13% 127
2024
Q1 		$1.11M Buy
9,205
+745
+9% +$91.3K 0.24% 80
2023
Q4 		$1.04M Buy
8,460
+3
+0% +$374 0.24% 82
2023
Q3 		$1.09M Sell
8,457
-130
-2% -$17.3K 0.28% 76
2023
Q2 		$1.06M Sell
8,587
-221
-3% -$29.7K 0.26% 81
2023
Q1 		$1.29M Hold
8,808
– – 0.33% 72
2022
Q4 		$1.4M Sell
8,808
-835
-9% -$122K 0.38% 63
2022
Q3 		$1.28M Hold
9,643
– – 0.36% 64
2022
Q2 		$1.5M Sell
9,643
-50
-0.5% -$7.7K 0.4% 56
2022
Q1 		$1.51M Buy
9,693
+537
+6% +$77.9K 0.36% 59
2021
Q4 		$1.17M Sell
9,156
-2,518
-22% -$331K 0.27% 75
2021
Q3 		$1.52M Buy
11,674
+1,779
+18% +$269K 0.38% 57
2021
Q2 		$1.76M Buy
9,895
+3
+0% +$520 0.45% 50
2021
Q1 		$1.63M Sell
9,892
-514
-5% -$84.6K 0.45% 49
2020
Q4 		$1.72M Sell
10,406
-2,291
-18% -$341K 0.52% 43
2020
Q3 		$1.81M Buy
12,697
+183
+1% +$22.7K 0.64% 37
2020
Q2 		$1.37M Buy
12,514
+850
+7% +$94K 0.51% 41
2020
Q1 		$1.12M Buy
11,664
+1,460
+14% +$189K 0.53% 42
2019
Q4 		$1.51M Buy
10,204
+1,015
+11% +$138K 0.51% 39
2019
Q3 		$1.16M Buy
9,189
+3,713
+68% +$498K 0.42% 46
2019
Q2 		$778K Buy
+5,476
New +$736K 0.29% 72

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Ellis Investment Partners's JAZZ Position: Q2 2026 in Review

Ellis Investment Partners held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 6,912 shares worth $1.67M. The position accounts for 0.25% of the portfolio, ranked #82.

Ellis Investment Partners first reported a position in JAZZ in Q2 2019 and has held it in 29 quarters since. The position peaked at $1.81M in Q3 2020. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Ellis Investment Partners held 6,912 shares of Jazz Pharmaceuticals worth $1.67M as of Q2 2026.
  • Ellis Investment Partners left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
  • Jazz Pharmaceuticals made up 0.25% of Ellis Investment Partners's portfolio in Q2 2026, its #82 holding.
  • Ellis Investment Partners first reported a position in Jazz Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Ellis Investment Partners's Jazz Pharmaceuticals position peaked at $1.81M in Q3 2020.
  • 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Ellis Investment Partners's 13F filing for Q2 2026, filed 5 Aug 2026.